HealthEquity vs Humana: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

HealthEquity Inc (HQY)

Humana Inc (HUM)

Latest6 Oct – 9 Oct 2026

▲3▼1

Humana's Star Ratings Rebound Restores Bonus Payments, Lifting Stock

Star Ratings Recovery Restores Bonus Payments CMS upgraded Humana's largest Medicare Advantage contract to 4 stars for 2027, and 95% of members will be in 4-star-plus plans, up from 20%. This restores federal quality bonus payments, boosting future earnings and lifting the stock 15%.
This is the main new event that directly answers why HUM is moving, with a clear positive impact.
Analyst Upgrade on Improved Earnings Outlook Baird upgraded Humana to Outperform with a $596 price target, up from $390, citing confidence in $35-plus of 2028 adjusted EPS. This analyst endorsement reinforces the positive sentiment from the Star Ratings news.
It shows a direct analyst reaction to the improved fundamentals, supporting the stock's move.
Expanded Coverage for Incontinence Device Humana will cover BlueWind Medical's Revi System for urgency urinary incontinence, expanding treatment access for its 11 million Medicare Advantage enrollees. This is a minor positive but shows Humana's role in adopting new technologies.
It is a new coverage decision that could marginally improve Humana's reputation and member satisfaction.
Medicare Advantage Industry Retrenchment Centene is exiting 344 counties and three states for 2027, and Humana plans to exit 57 counties and Minnesota, as premiums are expected to decline 16.5%. This industry-wide pullback reflects ongoing pressure on Medicare Advantage profitability.
It provides context on the challenging Medicare Advantage environment, a counterweight to the positive Star Ratings news.

Q3 20268 Jul – 1 Oct 2026

▼2▲1

Humana cuts 2026 profit outlook on star ratings drop

Star ratings cut triggers profit outlook reduction Humana lowered its 2026 profit forecast to at least $6.52 per share from $8.36 after fewer Medicare Advantage plans earned four-plus star ratings, reducing federal bonuses. Shares fell about 9% premarket.
This was the main negative event that drove the stock down during the quarter.
Strong Q2 earnings beat and membership growth Q2 adjusted earnings of $7.61 beat estimates by over 20%, with revenue up 26% to $40.9 billion and membership up 20.7%. This shows underlying business strength despite the outlook cut.
This positive result provided a counterweight to the negative star ratings news.
Margin recovery path and expansion offset by headwinds Humana reiterated a path to 3% margins by 2028, with weaker plan exits and Medicaid/home-health expansion. But risks include the end of a $3.6 billion Part D subsidy raising 2027 premiums and 600,000 MA members dropped for 2027.
This captures the balanced mix of positive strategic progress and negative regulatory/market pressures.
Medicare fraud settlement and sector cost pressures A $541.5 million Medicare fraud settlement highlighted upcoding scrutiny, and sector-wide medical cost pressures persist. These add regulatory and financial risks that could weigh on future profits.
This points to ongoing legal and cost challenges that could affect Humana's financial performance.

September 202614 Aug – 1 Oct 2026

▼3▲1

Humana cuts 600k MA members, Star Ratings recovery is key catalyst

Humana drops 600,000 Medicare Advantage members for 2027 Humana is cutting about 600,000 members from its Medicare Advantage plans next year, its second straight year of big cuts, to protect profit margins as medical costs rise. Fewer members means less premium revenue, which pressures the stock, though it may help margins.
This is the core new event driving Humana's outlook and was confirmed in this period.
Star Ratings recovery targeted as key catalyst Humana aims to return to top-quartile Star Ratings by 2028, which would boost bonus payments and plan economics. Early progress is encouraging, and the October CMS ratings release is the next test. A rebound could support the stock, though shares already trade at a high valuation.
Star Ratings recovery is a major potential upside driver for Humana's turnaround and margins.
Medicare fraud settlement and upcoding scrutiny The Villages Health settled a $541.5 million Medicare fraud case over inflated diagnosis codes. Humana's CenterWell unit is shielded from direct payment, but Humana received inflated payments and is returning overpayments. The case signals heightened government scrutiny on risk-adjustment practices, a regulatory risk for Humana.
This highlights a regulatory overhang that could affect Humana's payments and reputation.
Sector-wide cost pressures and macro headwinds Managed care stocks, including Humana, fell after CVS Health warned of elevated medical costs. Rising oil prices and Treasury yields added to market pressure. These sector-wide concerns weigh on Humana's stock, though they are not specific to the company.
This explains a broad negative sentiment affecting Humana's price during the period.

14 Aug – 1 Oct 2026

▼3▲1

Humana cuts 600k MA members, Star Ratings recovery is key catalyst

Humana drops 600,000 Medicare Advantage members for 2027 Humana is cutting about 600,000 members from its Medicare Advantage plans next year, its second straight year of big cuts, to protect profit margins as medical costs rise. Fewer members means less premium revenue, which pressures the stock, though it may help margins.
This is the core new event driving Humana's outlook and was confirmed in this period.
Star Ratings recovery targeted as key catalyst Humana aims to return to top-quartile Star Ratings by 2028, which would boost bonus payments and plan economics. Early progress is encouraging, and the October CMS ratings release is the next test. A rebound could support the stock, though shares already trade at a high valuation.
Star Ratings recovery is a major potential upside driver for Humana's turnaround and margins.
Medicare fraud settlement and upcoding scrutiny The Villages Health settled a $541.5 million Medicare fraud case over inflated diagnosis codes. Humana's CenterWell unit is shielded from direct payment, but Humana received inflated payments and is returning overpayments. The case signals heightened government scrutiny on risk-adjustment practices, a regulatory risk for Humana.
This highlights a regulatory overhang that could affect Humana's payments and reputation.
Sector-wide cost pressures and macro headwinds Managed care stocks, including Humana, fell after CVS Health warned of elevated medical costs. Rising oil prices and Treasury yields added to market pressure. These sector-wide concerns weigh on Humana's stock, though they are not specific to the company.
This explains a broad negative sentiment affecting Humana's price during the period.

July 20268 Jul – 4 Aug 2026

▲2▼2

Humana cuts profit outlook on lower star ratings; Q2 beat and growth plans

Medicare star rating drop cuts 2026 profit outlook Humana lowered its full-year GAAP earnings target to at least $6.52 per share from $8.36 because fewer plans earned four stars or more, reducing federal quality bonuses. This directly cuts expected profit and is the main reason the stock fell about 9% premarket.
This is the biggest new negative event and explains the profit outlook cut.
Q2 earnings beat on membership and revenue growth Humana reported adjusted earnings of $7.61 per share, beating estimates by over 20%, with revenue up 26% to $40.9 billion and medical membership up 20.7% to 17.9 million. Strong results show the core business is growing, which supports the stock.
This is a new positive counterweight to the profit outlook cut.
End of Medicare Part D subsidy raises 2027 premiums The Trump administration ended a subsidy that gave insurers about $3.6 billion in 2026. Without it, most enrollees will pay more in 2027, and insurers like Humana may see lower government payments and pressure on Part D margins, which is a negative for future profits.
This is a new regulatory change that affects Humana's future Medicare Part D business.
Operational streamlining and growth initiatives Humana is targeting a 3% margin by 2028, exiting weaker Medicare Advantage plans, and expanding Medicaid and home health through a $900 million divestiture and the MaxHealth acquisition. These moves aim to improve long-term profitability and offset star rating issues.
This shows management's plan to fix margins and grow, which is new and relevant to the big picture.

8 Jul – 4 Aug 2026

▲2▼2

Humana cuts profit outlook on lower star ratings; Q2 beat and growth plans

Medicare star rating drop cuts 2026 profit outlook Humana lowered its full-year GAAP earnings target to at least $6.52 per share from $8.36 because fewer plans earned four stars or more, reducing federal quality bonuses. This directly cuts expected profit and is the main reason the stock fell about 9% premarket.
This is the biggest new negative event and explains the profit outlook cut.
Q2 earnings beat on membership and revenue growth Humana reported adjusted earnings of $7.61 per share, beating estimates by over 20%, with revenue up 26% to $40.9 billion and medical membership up 20.7% to 17.9 million. Strong results show the core business is growing, which supports the stock.
This is a new positive counterweight to the profit outlook cut.
End of Medicare Part D subsidy raises 2027 premiums The Trump administration ended a subsidy that gave insurers about $3.6 billion in 2026. Without it, most enrollees will pay more in 2027, and insurers like Humana may see lower government payments and pressure on Part D margins, which is a negative for future profits.
This is a new regulatory change that affects Humana's future Medicare Part D business.
Operational streamlining and growth initiatives Humana is targeting a 3% margin by 2028, exiting weaker Medicare Advantage plans, and expanding Medicaid and home health through a $900 million divestiture and the MaxHealth acquisition. These moves aim to improve long-term profitability and offset star rating issues.
This shows management's plan to fix margins and grow, which is new and relevant to the big picture.

Q2 202617 Jun – 29 Jun 2026

▲3▼2

Humana wins Medicaid, pushes margin recovery, CenterWell grows

Illinois Medicaid win expands members Humana won a statewide Illinois Medicaid contract, adding members across all 102 counties starting January 2027. More members mean more premium revenue, which supports future earnings and makes the stock more attractive.
New contract directly expands Humana's revenue base.
AI gains may be competed away UBS says hospitals may benefit more from AI than insurers because insurers' efficiency gains are easily copied and competed away through pricing. This limits how much Humana can improve margins from AI, a headwind for profit growth.
Analyst view questions durability of insurer AI margin gains.
Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care among major Medicare Advantage insurers, including Humana. This raises regulatory and reputational risk, which could lead to stricter rules or fines, pressuring the stock.
Regulatory scrutiny can hurt Humana's Medicare Advantage business.
Margin recovery plan and strong Q1 Humana beat Q1 earnings estimates and targets insurance margins above 3% by 2028, with disciplined pricing and cost cuts. Strong results and a clear profit plan boost investor confidence, pushing the stock up.
New earnings and margin targets show improving profitability.
CenterWell drives growth beyond insurance CenterWell revenue jumped 19.7% to $6.1 billion, with growth in primary care, home health, and pharmacy. This diversification reduces reliance on insurance and adds a steady profit stream, supporting the stock.
CenterWell's strong growth is a key new driver of Humana's value.

June 202617 Jun – 29 Jun 2026

▲3▼2

Humana wins Medicaid, pushes margin recovery, CenterWell grows

Illinois Medicaid win expands members Humana won a statewide Illinois Medicaid contract, adding members across all 102 counties starting January 2027. More members mean more premium revenue, which supports future earnings and makes the stock more attractive.
New contract directly expands Humana's revenue base.
AI gains may be competed away UBS says hospitals may benefit more from AI than insurers because insurers' efficiency gains are easily copied and competed away through pricing. This limits how much Humana can improve margins from AI, a headwind for profit growth.
Analyst view questions durability of insurer AI margin gains.
Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care among major Medicare Advantage insurers, including Humana. This raises regulatory and reputational risk, which could lead to stricter rules or fines, pressuring the stock.
Regulatory scrutiny can hurt Humana's Medicare Advantage business.
Margin recovery plan and strong Q1 Humana beat Q1 earnings estimates and targets insurance margins above 3% by 2028, with disciplined pricing and cost cuts. Strong results and a clear profit plan boost investor confidence, pushing the stock up.
New earnings and margin targets show improving profitability.
CenterWell drives growth beyond insurance CenterWell revenue jumped 19.7% to $6.1 billion, with growth in primary care, home health, and pharmacy. This diversification reduces reliance on insurance and adds a steady profit stream, supporting the stock.
CenterWell's strong growth is a key new driver of Humana's value.

17 Jun – 29 Jun 2026

▲3▼2

Humana wins Medicaid, pushes margin recovery, CenterWell grows

Illinois Medicaid win expands members Humana won a statewide Illinois Medicaid contract, adding members across all 102 counties starting January 2027. More members mean more premium revenue, which supports future earnings and makes the stock more attractive.
New contract directly expands Humana's revenue base.
AI gains may be competed away UBS says hospitals may benefit more from AI than insurers because insurers' efficiency gains are easily copied and competed away through pricing. This limits how much Humana can improve margins from AI, a headwind for profit growth.
Analyst view questions durability of insurer AI margin gains.
Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care among major Medicare Advantage insurers, including Humana. This raises regulatory and reputational risk, which could lead to stricter rules or fines, pressuring the stock.
Regulatory scrutiny can hurt Humana's Medicare Advantage business.
Margin recovery plan and strong Q1 Humana beat Q1 earnings estimates and targets insurance margins above 3% by 2028, with disciplined pricing and cost cuts. Strong results and a clear profit plan boost investor confidence, pushing the stock up.
New earnings and margin targets show improving profitability.
CenterWell drives growth beyond insurance CenterWell revenue jumped 19.7% to $6.1 billion, with growth in primary care, home health, and pharmacy. This diversification reduces reliance on insurance and adds a steady profit stream, supporting the stock.
CenterWell's strong growth is a key new driver of Humana's value.